CAI is a potent inhibitor of neovascularization and imparts neuroprotection in a mouse model of ischemic retinopathy.
Franklin
Alan J
AJ
Department of Ophthalmology, University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA. alfranklin@aol.com <alfranklin@aol.com>
Jetton
Tom L
TL
Kuchemann
C Lynn
CL
Russell
Stephen R
SR
Kohn
Elise C
EC
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000818:Animals; D000831:Animals, Newborn; D000970:Antineoplastic Agents / Q000627:therapeutic use; D004195:Disease Models, Animal; D005451:Fluorescein Angiography; D018496:Hyperoxia / Q000150:complications; D020287:In Situ Nick-End Labeling; D007511:Ischemia / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D051379:Mice; D008810:Mice, Inbred C57BL; D018613:Microscopy, Confocal; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism; D015861:Retinal Neovascularization / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D012171:Retinal Vessels / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D014230:Triazoles / Q000627:therapeutic use*
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D018696:Neuroprotective Agents; D019253:Proto-Oncogene Proteins c-bcl-2; D014230:Triazoles; C062058:carboxyamido-triazole